The Therapeutic Goods Administration earlier this month issued a joint statement with several medical bodies confirming a shortage of Ozempic due to “unexpected increase in consumer demand” and called for professionals to only prescribe it appropriately.
“The increased demand is due to extensive prescribing for obesity management, for which Ozempic is not indicated. The shortage is significantly affecting people using Ozempic for its approved use for type 2 diabetes,” the statement read.
Royal Australian College of General Practitioners president, Dr Karen Price, warned there were side effects to using Ozempic to manage weight loss – such as nausea and vomiting – as well as contraindications if pregnant or breastfeeding.
“There are lots of issues people need to be aware of but most importantly, it’s not yet approved in Australia or the UK for weight loss. It’s being used off-label, which means that this huge demand is now stopping people who have a genuine need for the medication for their diabetes,” she told the Guardian.